Miyuki Hiratsuka
Overview
Explore the profile of Miyuki Hiratsuka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
10
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ichinose Y, Hasebe T, Hirasaki M, Sakakibara A, Yokogawa H, Nukui A, et al.
Pathol Int
. 2023 Jun;
73(9):413-433.
PMID: 37378453
Vimentin is a stable mesenchymal immunohistochemical marker and is widely recognized as a major marker of mesenchymal tumors. The purpose of the present study was to investigate if the vimentin...
2.
Hiratsuka M, Hasebe T, Ichinose Y, Sakakibara A, Fujimoto A, Wakui N, et al.
Virchows Arch
. 2022 Dec;
484(5):873.
PMID: 36580139
No abstract available.
3.
Hiratsuka M, Hasebe T, Ichinose Y, Sakakibara A, Fujimoto A, Wakui N, et al.
Virchows Arch
. 2022 Jun;
481(2):161-190.
PMID: 35695928
Tumor budding grade is a very useful histological prognostic indicator for colorectal cancer patients. Recently, it has been also reported as a significant prognostic indicator in invasive breast carcinoma patients....
4.
Fujimoto A, Matsuura K, Kawasaki T, Ichinose Y, Nukui A, Hiratsuka M, et al.
Oxf Med Case Reports
. 2021 Sep;
2021(9):omab083.
PMID: 34527256
Breast cancer arising from fibroadenoma (FA) is rare, in which almost all reported cases are human epidermal growth factor receptor 2 (HER2)-negative. This is the first report to describe a...
5.
Yamagishi Y, Koiwai T, Yamasaki T, Einama T, Fukumura M, Hiratsuka M, et al.
BMC Cancer
. 2019 Nov;
19(1):1146.
PMID: 31775675
Background: To evaluate the clinicopathological and prognostic significance of the percentage change between maximum standardized uptake value (SUV) at 60 min (SUV1) and SUV at 120 min (SUV2) (ΔSUV%) using...
6.
Yamagishi Y, Einama T, Yamasaki T, Koiwai T, Hiratsuka M, Fukumura M, et al.
Oncol Lett
. 2019 Mar;
17(3):2818-2824.
PMID: 30854057
The present study reports a case of metachronous bilateral breast cancer associated with neurofibromatosis type 1 (NF1). A 67-year-old female, who had undergone a radical mastectomy of the left breast...
7.
Suda H, Omori K, Suematsu Y, Hiratsuka M, Takahashi M, Saito H, et al.
Gan To Kagaku Ryoho
. 2016 Jan;
42(12):2388-90.
PMID: 26805373
Case 1: The patient was a 42-year-old man who was diagnosed with intraductal papillary-mucinous carcinoma with liver metastasis. After S-1+gemcitabine and S-1 chemotherapy, the liver metastasis had disappeared and we...
8.
Suematsu Y, Ishibashi Y, Hiratsuka M, Suda H, Takahashi M, Saito H, et al.
Gan To Kagaku Ryoho
. 2016 Jan;
42(12):2100-2.
PMID: 26805277
A 69-year-old woman was diagnosed with descending colon cancer with multiple liver metastases, and a left hemicolectomy was performed. The patient was treated with capecitabine/oxaliplatin (CapeOX) plus bevacizumab (Bmab). After...
9.
Hiratsuka M, Ishibashi Y, Suematsu Y, Suda H, Takahashi M, Saito H, et al.
Gan To Kagaku Ryoho
. 2016 Jan;
42(12):2061-2.
PMID: 26805264
Here, we report a 54-year-old man diagnosed with type 3 advanced gastric cancer who underwent a total gastrectomy and splenectomy plus D2 lymphadenectomy. The pathologic diagnosis was Stage Ⅳ (T3N0H0P0CY1M1)....
10.
Saito H, Suematsu Y, Hiratsuka M, Suda H, Takahashi M, Omori K, et al.
Gan To Kagaku Ryoho
. 2016 Jan;
42(12):2052-4.
PMID: 26805261
A 72-year-old man underwent surgery for advanced gastric cancer. Systemic chemotherapy was started, using a regimen of S-1/CDDP for 4 courses, followed by 8 courses of S-1. Three years and...